Biodesix
Biodesix Q1 Revenues Soar on COVID-19 Testing
For the three months ended March 31, the firm reported revenues of $28.9 million, compared to $5.1 million in the same period a year ago.
The firm will commercialize its Primary Immune Response assay as a laboratory-developed test to help guide immunotherapy decisions in lung cancer patients.
Biodesix Secures $30M Term Loan
The firm used the proceeds to repay outstanding borrowings of $25.9 million under its existing loan with Innovatus Life Sciences Lending Fund.Â
Biodesix Q4 Revenues More Than Triple on COVID-19 Testing
For the three months ended Dec. 31, the Boulder, Colorado-based firm reported revenues of $27.0 million compared to $8.3 million in 2019.
COVID-19 Pandemic Changing Digital Innovations, Care Models for Lab Industry, Panelists Say at ACLA
Premium
At ACLA's annual meeting, a panel discussed how machine learning, artificial intelligence, telehealth, and at-home testing have gained traction throughout the laboratory industry.